Resource Utilization and Cost-Effectiveness of Counselor-vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department

被引:9
作者
Walensky, Rochelle P. [1 ,2 ,3 ,7 ]
Morris, Bethany L. [2 ]
Reichmann, William M. [5 ,9 ]
Paltiel, A. David [8 ]
Arbelaez, Christian [6 ]
Donnell-Fink, Laurel [5 ]
Katz, Jeffrey N. [4 ,5 ]
Losina, Elena [5 ,7 ,9 ]
机构
[1] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA
[3] Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA
[8] Yale Univ, Sch Med, New Haven, CT USA
[9] Boston Univ Sch Publ Hlth, Dept Biostat, Boston, MA USA
来源
PLOS ONE | 2011年 / 6卷 / 10期
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; UNITED-STATES; OPPORTUNISTIC INFECTIONS; PREVENTION; LOPINAVIR/RITONAVIR; RECOMMENDATIONS; EMTRICITABINE; ADOLESCENTS;
D O I
10.1371/journal.pone.0025575
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Routine HIV screening in emergency department (ED) settings may require dedicated personnel. We evaluated the outcomes, costs and cost-effectiveness of HIV screening when offered by either a member of the ED staff or by an HIV counselor. Methods: We employed a mathematical model to extend data obtained from a randomized clinical trial of provider-vs. counselor-based HIV screening in the ED. We compared the downstream survival, costs, and cost-effectiveness of three HIV screening modalities: 1) no screening program; 2) an ED provider-based program; and 3) an HIV counselor-based program. Trial arm-specific data were used for test offer and acceptance rates (provider offer 36%, acceptance 75%; counselor offer 80%, acceptance 71%). Undiagnosed HIV prevalence (0.4%) and linkage to care rates (80%) were assumed to be equal between the screening modalities. Personnel costs were derived from trial-based resource utilization data. We examined the generalizability of results by conducting sensitivity analyses on offer and acceptance rates, undetected HIV prevalence, and costs. Results: Estimated HIV screening costs in the provider and counselor arms averaged $8.10 and $31.00 per result received. The Provider strategy (compared to no screening) had an incremental cost-effectiveness ratio of $58,700/quality-adjusted life year (QALY) and the Counselor strategy (compared to the Provider strategy) had an incremental cost-effectiveness ratio of $64,500/QALY. Results were sensitive to the relative offer and acceptance rates by strategy and the capacity of providers to target-screen, but were robust to changes in undiagnosed HIV prevalence and programmatic costs. Conclusions: The cost-effectiveness of provider-based HIV screening in an emergency department setting compares favorably to other US screening programs. Despite its additional cost, counselor-based screening delivers just as much return on investment as provider based-screening. Investment in dedicated HIV screening personnel is justified in situations where ED staff resources may be insufficient to provide comprehensive, sustainable screening services.
引用
收藏
页数:10
相关论文
共 53 条
  • [11] [Bureau of HIV/STD Viral Hepatitis Prevention], 2008, ROUT OPT OUT HIV SCR
  • [12] Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1051
  • [13] Department of Health and Human Services, 2011, GUID US ANT AG HIV I
  • [14] Cost comparison of three HIV counseling and testing technologies
    Ekwueme, DU
    Pinkerton, SD
    Holtgrave, DR
    Branson, BM
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2003, 25 (02) : 112 - 121
  • [15] Farnham PG, 1996, PUBLIC HEALTH REP, V111, P44
  • [16] The cost-effectiveness of preventing AIDS-related opportunistic infections
    Freedberg, KA
    Scharfstein, JA
    Seage, GR
    Losina, E
    Weinstein, MC
    Craven, DE
    Paltiel, AD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (02): : 130 - 136
  • [17] The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg, KA
    Losina, E
    Weinstein, MC
    Paltiel, AD
    Cohen, CJ
    Seage, GR
    Craven, DE
    Zhang, H
    Kimmel, AD
    Goldie, SJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 824 - 831
  • [18] Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Gallant, JE
    DeJesus, E
    Arribas, JR
    Pozniak, AL
    Gazzard, B
    Campo, RE
    Lu, B
    McColl, D
    Chuck, S
    Enejosa, J
    Toole, JJ
    Cheng, AK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) : 251 - 260
  • [19] Gebo Kelly A, 2003, Hopkins HIV Rep, V15, P5
  • [20] George Cindy., 2009, Houston Chronicle